Prior to joining BioMap, Per spent several years at Novo Nordisk, where he was Vice President for Computational Drug Design and also served as an interim VP for Research Engineering.. Per established and led the De Novo Protein Design Group of Novo Nordisk, driving significant advancements in protein engineering and discovery. He was part of multiple protein engineering programs and achieved notable successes, including Mim8 which is currently in Phase 3. Per has also benefitted from experience in startups including Enevolv (now Gingko Bioworks) who he joined in 2019 in Boston, specializing in protein engineering, and was part of engineering SYNB1934 (Phase III). Per received his bachelor’s degree in Biochemistry and master’s degree in Bioinformatics from the University of Copenhagen. He started his PhD in quantum mechanics, neural networks, and protein folding but he quickly pivoted his research area to computational protein design. In 2012 Per went to the University of Washington to focus on computational protein design of metalloproteins in David Baker’s Lab where he led work on the evolution of enzymes and small molecule binders.